More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
Researchers tracked outcomes data and imaging results from nearly 4,000 TEER patients, sharing their findings in the Journal of the American College of Cardiology.
Research presented this week at the American Society for Radiation Oncology Annual 2022 Meeting argues for the inclusion of radiation therapy as a standard of care in liver cancer patients who are ineligible for resection and other standard therapies.
“Because patients with aortic stenosis are old and commonly have chronic kidney disease, it is essential to evaluate the renal function before TAVR," the study's authors wrote. “Albuminuria indicates glomerular injury and is an important factor in the assessment of renal function or diagnosis of chronic kidney disease."
Might mammography enhanced by contrast media prove a surer, faster way than other modalities—including digital breast tomosynthesis—to get to a definitive diagnosis for women with dense breast tissue? The American College of Radiology wants to know.
Reviewing data from more than 23.5 million U.S. patients, the study's authors found that methamphetamine use was linked to a whopping 86% increase in a patient's AFib risk. The other substances included in the analysis were not far behind.
The adult brain may be more malleable than scientists previously thought, according to new research presented at the 35th European College of Neuropsychopharmacology.
Children are at heightened risk of major clinical depression when at least one parent has a history of the disorder. New research shows depression markers appearing on structural and functional brain MRI ahead of symptoms in these “familial risk” offspring from infancy through early adulthood.
